Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
  1. Predictions
buy

Esperion Therapeutis.Inc. buy OrderProvision70

Esperion Therapeutis.Inc.
Start price
€0.79
18.04.25 / 50%
Target price
-
18.05.25
Performance (%)
-8.23%
End price
€0.72
19.05.25
Summary
This prediction ended on 19.05.25 with a price of €0.72. With a performance of -8.23%, the BUY prediction by OrderProvision70 finished with a loss. OrderProvision70 has 50% into this prediction

Esperion Therapeutics, Inc. (NASDAQ: ESPR) is a biopharmaceutical company primarily focused on the development and commercialization of innovative lipid management therapies to address the unmet medical needs of patients with high cholesterol. With its flagship products, NEXLETOL® and NEXLIZET®, the company aims to provide alternative treatment options for individuals who cannot tolerate statins or require additional LDL-C lowering despite statin therapy. Esperion is driven by its commitment to improve cardiovascular health globally and maintains a steadfast dedication to researching and developing advanced cholesterol-lowering therapies.

Performance without dividends (%)
Name 1w 1m
Esperion Therapeutis.Inc. -6.346% -6.346%
iShares Core DAX® 2.331% 5.140%
iShares Nasdaq 100 2.077% 2.956%
iShares Nikkei 225® 2.759% 7.214%
iShares S&P 500 1.613% 2.893%

Comments by OrderProvision70 for this prediction

In the thread Trading Esperion Therapeutis.Inc.
Prediction Buy
Perf. (%) -8.23%
Target price
Change
Ends at 18.05.25

Die von OrderProvision70 gewählte maximale Laufzeit wurde überschritten

OrderProvision70 
0
Report Share
19.05.25